Document is current
Any future updates will be listed below
-
Authors
Galbiati, Francesca
Hiranandani, Sarah
Wronski, Marie-Louis
Plessow, Franziska
Holman, Katherine
Asanza, Elisa
Smith, Sarah E.
Muhammed, Maged
Golden, Emily R.
Hadaway, Natalia
Getachew, Ethiopia
Misra, Madhusmita
Aulinas, Anna
Lawson, Elizabeth A. https://orcid.org/0000-0001-8619-3349
- License Information
-
More Information
Article History
Received: 16 September 2025
Revised: 18 February 2026
Accepted: 17 March 2026
First Online: 9 April 2026
Competing interests
: EAL receives grant support and research study drug from Tonix Pharmaceuticals and receives royalties from UpToDate. EAL and/or immediate family member holds stock in Thermo Fisher Scientific, Zoetis, Danaher Corporation, Intuitive Surgical, Merck, West Pharmaceutical Services, Gilead Sciences, and Illumina. EAL and FP are inventors on PCTUS2025/030536 entitled, “Oxytocin-based therapeutics to improve cognitive control in individuals with attention deficit hyperactive disorder” filed on May 22, 2025. MM has consulted for Regeneron and Kyss Pharmaceuticals, receives study drug donation from Tonix Pharmaceuticals and Amgen, and royalties from UpToDate. Other authors declare no conflicts of interest related to this study.
: This trial was approved by the Mass General Brigham Institutional Review Board and conducted at Massachusetts General Hospital under a U.S. Food and Drug Administration Investigational New Drug application, in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and was overseen by a Data Safety and Monitoring Board. Participants gave written informed consent before procedures.
